Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares rose 15.2% during trading on Thursday . The company traded as high as $6.27 and last traded at $5.39. Approximately 2,799,590 shares traded hands during mid-day trading, an increase of 227% from the average daily volume of 857,225 shares. The stock had previously closed at $4.68.
MRNS has been the subject of a number of research analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $19.00 target price on shares of Marinus Pharmaceuticals in a research note on Monday, September 17th. BidaskClub upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th. Mizuho restated a “buy” rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, August 2nd. Finally, ValuEngine upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Marinus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $19.67.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Monday, October 29th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.06). On average, research analysts predict that Marinus Pharmaceuticals Inc will post -0.88 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in shares of Marinus Pharmaceuticals in the 1st quarter worth $373,000. Barclays PLC bought a new stake in shares of Marinus Pharmaceuticals in the 1st quarter worth $232,000. Jennison Associates LLC increased its holdings in shares of Marinus Pharmaceuticals by 0.8% in the 2nd quarter. Jennison Associates LLC now owns 2,757,356 shares of the biopharmaceutical company’s stock worth $19,495,000 after purchasing an additional 21,733 shares in the last quarter. Alps Advisors Inc. bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth $416,000. Finally, Rhumbline Advisers bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth $245,000. Institutional investors and hedge funds own 63.68% of the company’s stock.
Marinus Pharmaceuticals Company Profile (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Featured Article: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.